DUBLIN--(BUSINESS WIRE)--Jun 13, 2019--

Chronic Myeloid Leukemia Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Chronic Myeloid Leukemia market. It covers emerging therapies for Chronic Myeloid Leukemia in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Chronic Myeloid Leukemia pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Chronic Myeloid Leukemia pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.


The report provides Chronic Myeloid Leukemia pipeline products by the company.

Short-term Launch Highlights:

Find out which Chronic Myeloid Leukemia pipeline products will be launched in the US and Ex-US till 2024.

Key Topics Covered:

1. Chronic Myeloid Leukemia Pipeline by Stages

2. Chronic Myeloid Leukemia Phase 3 Clinical Trial Insights

3. Chronic Myeloid Leukemia Phase 2 Clinical Trial Insights

4. Chronic Myeloid Leukemia Phase 1 Clinical Trial Insights

5. Chronic Myeloid Leukemia Preclinical Research Insights

6. Chronic Myeloid Leukemia Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/vtivwj

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Leukemia Drugs,Clinical Trials



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 06/13/2019 05:00 AM/DISC: 06/13/2019 05:01 AM

Copyright Business Wire 2019.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.